Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma

NCT ID: NCT01307592

Last Updated: 2014-01-10

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-02-28

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, oxaliplatin, and , work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Lenalidomide may stop the growth of non-Hodgkin lymphoma by blocking blood flow to the cancer. Giving rituximab and chemotherapy together with lenalidomide may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving rituximab, gemcitabine hydrochloride, and oxaliplatin together with lenalidomide works in treating patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.

Detailed Description

OBJECTIVES:

Primary

• To determine the rate of conversion to complete response (CR) after switching to lenalidomide in patients with relapsed or refractory, aggressive non-Hodgkin lymphoma whose maximum response to gemcitabine hydrochloride, rituximab, and oxaliplatin is a partial response (PR).

Secondary

• To determine the overall survival of these patients treated with this regimen.
• To determine the progression-free survival of patients with CR and PR.
• To determine the treatment-related toxicity of this regimen combination in these patients.

OUTLINE: This is a multicenter study.

• Rituximab, gemcitabine hydrochloride, and oxaliplatin: Patients with B-cell lymphoma receive rituximab IV on day 1; all patients receive gemcitabine hydrochloride IV over 30 minutes and oxaliplatin IV over 2 hours on day 1 or day 2*. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

NOTE: *Patients with T-cell lymphoma proceed to chemotherapy on day 1 without receiving rituximab; patients with B-cell lymphoma receive chemotherapy on day 2.

Patients are reevaluated after 4 courses of therapy. Patients who achieve a complete response (CR) receive 2 more courses of therapy and then proceed to bone marrow transplantation (BMT); those that do not receive a BMT receive maintenance lenalidomide for 2 years. Patients who achieve a partial response (PR) and who are not candidate for autologous stem cell transplantation (ACT) are treated with lenalidomide**. Once patients with PR achieve a CR or < CR with lenalidomide treatment, they proceed to maintenance lenalidomide for 2 years, unless they become candidates for ACT***. Patients with stable disease or progressive disease after 4 courses of therapy are treated with lenalidomide, unless they become eligible for ACT***.

NOTE: **Patients in whom a delay of > 4 months would occur for ACT are treated with lenalidomide until 3 weeks prior to ACT.

NOTE: **Once eligible, patients proceed to ACT as soon as feasible.

• Maintenance lenalidomide: Patients receive oral lenalidomide once daily on days 1-21. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

Blood samples are collected at baseline and periodically for toxicity analysis.

After completion of study treatment, patients are followed up at 28 days and then every 3 months thereafter.

Conditions

Lymphoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

rituximab

Intervention Type: BIOLOGICAL

gemcitabine hydrochloride

Intervention Type: DRUG

lenalidomide

Intervention Type: DRUG

oxaliplatin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed aggressive non-Hodgkin lymphoma, including any of the following subtypes:

• Follicular large cell lymphoma
• Diffuse large cell lymphoma
• Peripheral T-cell lymphoma
• Transformed lymphoma
• Lymphoblastic lymphoma
• Burkitt or Burkitt-like lymphoma
• Refractory or relapsed disease meeting the following criteria:

• Patients who either did not respond to prior therapy or whose best response was partial response after ≥ 4 courses of chemotherapy
• Histologic confirmation of relapsed or refractory disease is desirable but not mandatory and will be left to the discretion of the investigator
• Must have evaluable or measurable disease
• Patients who are candidates for stem cell or bone marrow transplantation allowed
• No CNS involvement by lymphoma

PATIENT CHARACTERISTICS:

• ECOG performance status 0-3
• Absolute neutrophil count ≥ 1,000/mm³ (unless due to marrow infiltration by lymphoma)
• Platelet count ≥ 100,000/mm³ (unless thrombocytopenia is due to marrow infiltration by lymphoma)
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN) (unless liver is involved with lymphoma, hemolysis, or Gilbert syndrome)
• Serum creatinine ≤ 2.0 mg/dl or creatinine clearance ≥ 30 ml/min (unless creatinine elevation is due to lymphoma)
• ALT ≤ 2 times ULN (≤ 5 times ULN if liver metastasis is involved with lymphoma)
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective double-method contraception for ≥ 28 days before, during, and for ≥ 28 days after completion of study therapy

• Men must use latex condoms even after a successful vasectomy
• Must be enrolled in the mandatory RevAssist® program and be willing to comply with its requirements
• No neurosensory or neuromotor dysfunction ≥ grade 3
• No known HIV positivity or active hepatitis B or C (hepatitis B surface antigen positivity or hepatitis C RNA positivity)
• No known hypersensitivity to thalidomide or erythema nodosum characterized by desquamating rash while taking thalidomide or other similar drugs
• No history of allergy to platinum or any of its derivatives or E. coli-derived products
• No other malignancies within the past 5 years, except treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or any surgically cured malignancy from which the patient has been disease-free for ≥ 5 years
• No NYHA class III-IV congestive heat failure (no symptoms on less than ordinary exertion or at rest)
• No uncontrolled or intercurrent disease, including any of the following:

• Arrhythmias
• Angina pectoris
• Active infection or fever > 38.2 C (unless due to lymphoma)
• No serious medical condition, laboratory abnormality, or psychiatric illness that would place patient at risk in study or confound ability to interpret study data

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No prior gemcitabine hydrochloride, oxaliplatin, or lenalidomide
• Prior rituximab allowed
• No more than 4 prior regimens of chemotherapy allowed, including stem cell or bone marrow transplantation
• More than 2 weeks since prior and no concurrent anticancer therapy, including radiotherapy, hormonal therapy, or surgery
• More than 3 weeks since prior chemotherapy or radiotherapy
• More than 28 days since prior and no other concurrent investigational drug trial or investigational agent
• Able to take aspirin (81 mg or 325 mg) daily or low molecular weight heparin as prophylactic anticoagulation
• No concurrent thalidomide

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Auxilio Mutuo Cancer Center

OTHER

Sponsor Role: lead

Principal Investigators

Fernando Cabanillas, MD

Role: PRINCIPAL_INVESTIGATOR

Auxilio Mutuo Cancer Center

Locations

Centro de Cancer del Hospital Auxilio Mutuo

San Juan, , Puerto Rico

Site Status: RECRUITING

Countries

Puerto Rico

Facility Contacts

Clinical Trial Coordinator

Role: primary

iliboy@auxiliomutuo.com

787-771-7933 ext. 3569

Other Identifiers

CAM-09-01

Identifier Type: -

Identifier Source: secondary_id

CELGENE-RV-NHL-PI-0452

Identifier Type: -

Identifier Source: secondary_id

CDR0000695874

Identifier Type: -

Identifier Source: org_study_id